6598 Stock Overview
Designs, develops, and commercializes multiplex diagnostic testing products in California. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Applied BioCode Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$20.20 |
52 Week High | NT$33.60 |
52 Week Low | NT$19.20 |
Beta | 0.66 |
1 Month Change | -9.01% |
3 Month Change | -14.95% |
1 Year Change | -16.36% |
3 Year Change | -58.48% |
5 Year Change | -48.46% |
Change since IPO | -70.94% |
Recent News & Updates
Recent updates
Applied BioCode Corporation's (TWSE:6598) Shares Climb 33% But Its Business Is Yet to Catch Up
Jun 19We're Interested To See How Applied BioCode (TPE:6598) Uses Its Cash Hoard To Grow
Mar 31Introducing Applied BioCode (TPE:6598), A Stock That Climbed 11% In The Last Three Years
Feb 03Breakeven On The Horizon For Applied BioCode Corporation (TPE:6598)
Dec 11Shareholder Returns
6598 | TW Medical Equipment | TW Market | |
---|---|---|---|
7D | 0.2% | -0.2% | 2.5% |
1Y | -16.4% | -4.5% | 32.2% |
Return vs Industry: 6598 underperformed the TW Medical Equipment industry which returned -4.5% over the past year.
Return vs Market: 6598 underperformed the TW Market which returned 32.2% over the past year.
Price Volatility
6598 volatility | |
---|---|
6598 Average Weekly Movement | 3.6% |
Medical Equipment Industry Average Movement | 3.6% |
Market Average Movement | 4.4% |
10% most volatile stocks in TW Market | 7.8% |
10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6598 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6598's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | Winston Z. Ho | www.apbiocode.com |
Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. The company’s products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the PCR amplification, hybridization, and detection steps of molecular testing; and the BioCode 2500 analyzer, a system that reads barcoded magnetic beads (BMB) and displays the barcode and fluorescence intensity for each BMB. It develops assays, such as BioCode SARS-CoV-2 Assay, a nucleic acid assay for the detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs; and CoV-2 Flu Assay for detection of RNA and various Influenza, as well as offers gastrointestinal and respiratory pathogen panel related products.
Applied BioCode Corporation Fundamentals Summary
6598 fundamental statistics | |
---|---|
Market cap | NT$2.08b |
Earnings (TTM) | -NT$198.53m |
Revenue (TTM) | NT$386.31m |
5.4x
P/S Ratio-10.5x
P/E RatioIs 6598 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6598 income statement (TTM) | |
---|---|
Revenue | NT$386.31m |
Cost of Revenue | NT$124.76m |
Gross Profit | NT$261.56m |
Other Expenses | NT$460.09m |
Earnings | -NT$198.53m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.93 |
Gross Margin | 67.71% |
Net Profit Margin | -51.39% |
Debt/Equity Ratio | 0% |
How did 6598 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/08 18:31 |
End of Day Share Price | 2025/01/08 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Applied BioCode Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Xiaowei Huang | Masterlink Securities Corp. |